Last updated: October 21, 2024
Sponsor: University of Florida
Overall Status: Active - Recruiting
Phase
N/A
Condition
Liver Disease
Liver Disorders
Treatment
Alpha-1 Antitrypsin Genotype
Clinical Study ID
NCT00500123
IRB201903430
All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis ofsymptoms or family genetic risk.
Exclusion
Exclusion Criteria:
- Any person who has already had genotype and AAT level testing completed and has aqualified result.
Study Design
Total Participants: 50000
Treatment Group(s): 1
Primary Treatment: Alpha-1 Antitrypsin Genotype
Phase:
Study Start date:
January 01, 2001
Estimated Completion Date:
January 31, 2050
Study Description
Connect with a study center
University of Florida
Gainesville, Florida 32610
United StatesActive - Recruiting
Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine
Charleston, South Carolina 29425
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.